These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 32380458)

  • 1. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
    Mehta-Shah N; Horwitz SM; Ansell S; Ai WZ; Barnes J; Barta SK; Clemens MW; Dogan A; Fisher K; Goodman AM; Goyal G; Guitart J; Halwani A; Haverkos BM; Hoppe RT; Jacobsen E; Jagadeesh D; Lunning MA; Mehta A; Olsen EA; Pro B; Rajguru SA; Shanbhag S; Shaver A; Shustov A; Sokol L; Torka P; Torres-Cabala C; Wilcox R; William BM; Zain J; Dwyer MA; Sundar H; Kim YH
    J Natl Compr Canc Netw; 2020 May; 18(5):522-536. PubMed ID: 32380458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.
    Giordano A; Pagano L
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022029. PubMed ID: 35444765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
    Chung CG; Poligone B
    Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
    Stuver R; Geller S
    Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
    Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
    Atilla PA; Atilla E
    Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
    Photiou L; van der Weyden C; McCormack C; Miles Prince H
    Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
    Xu S; Foss F
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
    Olsen EA
    Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL.
    Brazel D; Pinter-Brown L
    Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):401-409. PubMed ID: 37061415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.